## **Approach to Ascites**

Paul Martin MD, FRCP, FRCPI Division of Hepatology, University of Miami.

# 62 year old man referred with abdominal distension.

- Remote icteric illness during college
- Describes himself as social drinker

### P/E mild muscle wasting, BP 110/70, Pulse 90/minute, afebrile

 Mild flank distension, diminished liver span with splenic dullness ? Shifting dullness, no fluid wave

## Initial Labs: Bilirubin 1.9 mgs/dl, AST 70, ALT 23, alk phos 135, platelet count 110 k, INR 1.2

Ultrasound perfomed

#### Ultrasound is the Most Sensitive Method to Detect Ascites







#### Initial workup

## **Diagnostic Paracentesis**

Indications

- New-onset ascites
- Admission to hospital
- Symptoms/signs of SBP
- Renal dysfunction
- Unexplained encephalopathy

None





INITIAL WORKUP OF ASCITES: DIAGNOSIS PARACENTESIS

#### Initial Workup of Ascites Diagnostic Paracentesis



# Ascites Fluid Analysis: Mandatory Tests

#### Cell count

- WBC & RBC
- Purple top tube
- Serum albumin ascites albumin gradient (SAAG)
  - Terms exudate & transudate
    - Should no longer be used
    - Apply to only pleural effusions
- Cultures
  - 10-20 ml in blood culture bottles

#### Ascites Can Be Characterized by Serum-Ascites Albumin Gradient (SAAG) and Ascites Protein Source

ascites **Hepatic sinusoids** Peritoneum **SAAG > 1.1** SAAG < 1.1 "Capillarized" sinusoid Normal "leaky" sinusoid Peritoneal lymph Ascites protein < 2.5 Ascites protein > 2.5Ascites protein > 2. **Post-sinusoidal Peritoneal pathology** Sinusoidal - Malignancy hypertension hypertension - Tuberculosis -Cirrhosis - Cardiac ascites -Late Budd-- Early Budd-Chiari - Veno-occlusive Chiari disease

## **Etiology of Ascites**



# Ascites Fluid Analysis: Optional Tests

#### Infected ascites

- Total protein, LDH & glucose

Gram stain

- To R/O free perforation of the gut
- Not for SBP (10% sensitive)
- Milky ascites
  - TG > 200 mg/ml
  - Occasionally high WBC count
- Malignant ascites
  - LDH (ascites > serum)
  - Cytology

# Ascites Classification: High Gradients

- Serum albumin ascites albumin (SAAG) > 1.1
- Portal hypertension present (90-95%)
- Causes
  - Liver
    - Cirrhosis
    - Very severe, acute hepatitis
    - Cancer: massive liver mets
  - Venous
    - Budd-Chiari syndrome
    - Veno-occlusive disease
    - Portal vein thrombosis
  - Cardiac (R-CHF, constrictive pericarditis)

# Ascites Classification: Low Gradients

- Serum albumin ascites albumin (SAAG) < 1.1 g/dL
- Causes (every other organ in the abdomen)
  - Perforated gastric ulcer
  - Ruptured gallbladder / biliary leak
  - Infarcted bowel
  - Pancreatitis
  - Renal
    - Nephrotic syndrome
    - Ruptured urinary bladder
  - Peritoneum
    - Infectious
    - Coboor





62 year old man with ascites

Ascites tapped: albumin 1.1 g/dl, wbc < 250,serum albumin 3.1 g/dl</li>

- SAAG: 2 consistent with portal hypertension
- HCV antibody positive,: diagnosis cirrhosis



## Initial management

# Management of Uncomplicated Ascites

Definition: Ascites responsive to diuretics in the absence of infection and renal dysfunction

Sodium restriction

- Effective in 10-20% of cases
- Predictors of response: mild or moderate ascites, Urine Na excretion > 50 mEq/day

Diuretics

- Should be spironolactone-based
- A progressive schedule (spironolactone → furosemide) requires fewer dose adjustments than a combined therapy (spironolactone + furosemide)



# Definition and Types of Refractory Ascites

Occurs in ~10% of cirrhotic patients

• Diuretic-intractable ascites **80%** 

Therapeutic doses of diuretics cannot be achieved because of diuretic-induced complications

• Diuretic-resistant ascites 20%

No response to maximal diuretic therapy (400 mg spironolactone + 160 mg furosemide/day)





#### **Beyond diuretics**

## **Ascites: Other Options**

 Repeated Large Volume Paracentesis: inconvenient, if required < every 2 weeks suggests non-compliance with salt and fluid restriction

 TIPS: used to manage ascites, recurrent variceal hemorrhage, hepatic hydrothorax etc. May worsen liver disease

## **TIPS Blood Flow Changes**



#### Compared to LVP, TIPS Reduces Ascites Recurrence But Increases Risk of Encephalopathy

|   | LVP            | TIPS               | р     |
|---|----------------|--------------------|-------|
|   | (n=35)         | (n=35)             |       |
| Recurrent ascites                                     | 11.7+2.7*      | 3.6 + 1.70         | 0.003 |
| <b>TIPS</b> obstruction                               | -              | 40%                | -     |
| Grade 3-4 PSE   | $0.5 \pm 0.02$ | 1.1 ± 0.02         | 0.02  |
| Death   | 51%            | 57%                | ns    |
| Gines et al., Gastroenterology 2002; 12 <u>3:1839</u> |                | * Episodes/patient |       |

## **Ascites: Other Options**

 Peritoneovenous shunt: largely replaced by TIPS

 Pleurx catheter; left in situ, used in malignant ascites

#### Peritoneo-Venous Shunt (PVS) is Useful in the Treatment of Refractory Ascites

Use of jugular vein will hinder TIPS placement

> One-way valve

Intraabdominal adhesions may complicate liver transplant surgery



## **Ascites: Survival & OLT**



## Cirrhosis

Background

Fibrosis

Regenerative nodule

#### Normal Hepatic SInusoid

Fenestrae —

Space of Disse

Sinusoidal endothelial cell Retinoid droplets

> Hepatic stellate cell

Hepatocytes

#### Alterations in Microvasculature in Cirrhosis

- Activation of stellate cells
- Collagen deposition in space of Disse
- Constriction of sinusoids
- Defenestration of sinusoids

In Cirrhosis, Nitric Oxide (NO) Activity is Reduced and Vasoconstrictors (VC) are Increased

VC

VC

VC

NO

VC

JC

JC

NO

.C

VC

## Cirrhosis

Prognosis

#### Stable cirrhosis in absence of complications

(Fattovich, Gastroenterology 1997)



Platelets <115,000 > predictor

## **Stable Cirrhotic**

- Routine Health Maintenance
- Surveillance for HCC
- Screening and prophylaxis of varices
- SBP prophylaxis

## Management of the stable cirrhotic: HCC surveillance

- Cirrhosis is high risk factor for HCC: 23 fold risk after 3.5 years (Chalasani, Amer J Gastr 1999)
- If presenting with symptoms, median survival is 4 months
- Surveillance:
  - AFP sensitivity 64%/specificity 91%
    UTZ sensitivity 59-74%/specificity 94%
    Optimal frequency unknown

## Cirrhosis

Complications

#### Development of Complications in Compensated Cirrhosis


### **Decompensation Shortens Survival**



A Gines et. al., Hepatology 1987;7:122

#### Complications of Cirrhosis Result from Portal Hypertension or Liver Insufficiency





# Cirrhosis

Varices

#### Prevalence and Size of Esophageal Varices in Patients with Newly-Diagnosed Cirrhosis



Pagliaro et al., In: Portal Hypertension: Pathophysiology and Management, 1994: 72

#### Large Varices are more Likely to Rupture



\*Merli et al., Hepatol 2003; 38:266, \*\*Conn et al., Hepatology 1991; 13:902

### Varices Increase in Diameter Progressively







Variceal hemorrhage Varix Predictors of hemorrhage: • Variceal size

- Red signs
- Child B/C

A NIEC. N Engl J Med 1988; 319:983

### **Treatment of Acute Variceal Hemorrhage**

General Management:

- IV access and fluid resuscitation
- Do not overtransfuse (hemoglobin ~ 8 g/dL)
- Antibiotic prophylaxis

#### Specific therapy:

- Pharmacological therapy: terlipressin, somatostatin and analogues, vasopressin + nitroglycerin
- Endoscopic therapy: ligation, sclerotherapy
- Shunt therapy: TIPS, surgical shunt



# Probability of Remaining Free of Recurrent Variceal Hemorrhage



Hou M-C et al., Hepatology 2004; 39:746







### **Gastric Varices**

- 10-15% of variceal bleeding episodes
- Limited data from controlled trials
- Optimal therapy not known
- Vasoactive drugs used.
- Endoscopic cyanoacrylate injection: 90% control of bleeding
- Balloon tamponade with Linton-Nachlas tube
- TIPS: 90% control of bleeding



#### Management of Bleeding Gastric Varices



\*Surgical shunt may be considered for Child's Class A

## Cirrhosis

#### **Spontaneous Bacterial Peritonitis**

#### Spontaneous Bacterial Peritonitis (SBP) is the Most Common Infection in Cirrhotic Patients



Fernández et al., Hepatology 2002; 35:140

MANAGEMENT ALGORITHM IN SPONTANEOUS BACTERIAL PERITONITIS (SBP)

#### Diagnosis and Management of Spontaneous Bacterial Peritonitis



### **Clinical Characteristics of Spontaneous Bacterial Peritonitis**



#### Mortality Associated with SBP has been Decreasing by Early Diagnosis and Treatment



#### Spontaneous Bacterial Peritonitis Use of Intravenous Albumin

Albumin (plus antibiotics) is indicated if:

- BUN > 30 mg/dL
- creatinine > 1.0 mg/dL
- bilirubin > 4 mg/dL

Albumin is not indicated in patients with a predicted 100% cure and survival:

- community-acquired SBP
- no GI hemorrhage
- no encephalopathy
- normal renal function



Indications for Prophylactic Antibiotics to Prevent Spontaneous Bacterial Peritonitis

- Cirrhotic patients hospitalized with GI hemorrhage (short-term)
  - Norfloxacin 400 mg p.o. BID x 7 days
- Patients who have recovered from SBP (long-term)
  Norfloxacin 400 mg p.o. daily, indefinitely
- Weekly quinolones not recommended (lower efficacy, development of quinolone-resistance)
- Patients with low albumin in ascitic fluid.

### Cirrhosis

#### Hepatorenal Syndrome

### **Two Types of Hepatorenal Syndrome**

Type 1

- Rapidly progressive renal failure (2 weeks)
- Doubling of creatinine to >2.5 or halving of creatinine clearance (CrCl) to <20 ml/min</li>

Type 2

- More slowly progressive
- Creatinine >1.5 mg/dL or CrCl < 40 ml/min</li>
- Associated with refractory ascites

Arroyo et al., Hepatology 1996; 23:164

#### Survival in Different Types of Hepatorenal Syndrome (HRS)



Gines et al., Lancet 2003; 362:1819

## Cirrhosis

#### Liver Transplantation

# Patient Selection Criteria for LT

- Accepted indications for LT
  - Advanced chronic liver disease
  - Acute liver failure
  - Unresectable hepatic malignancy
  - Inherited metabolic liver disease
- No alternative form of therapy
- No absolute contraindication to LT
- Willingness to comply with follow-up care
- Ability to provide for costs of LT

### **Evaluation Process**

- Assessment of Liver Disease Severity and Prognosis
- Presence of Complications

Comorbidities

Psychosocial Issues and Support

### **Evaluation Process**

- Routine Biochemical and Hematological Panels (CBC, Creat. INR, LFTs, ABO)
- Serological Screen (Hepatitis Panel, HIV, EBV, CMV)
- Imaging of Abdomen
- Medical Consultations and Evaluations as clinically indicated (e.g. ID, Cardiology)
- Age appropriate Cancer Screening

# **MELD and Survival**



### Liver Transplantation in the U.S. Current Status

- 1-year patient survival: 85–90% in most centers
- 3-year survival 75-80%; 8-year survival 60-70%
- ~6,000 LT/year last 3 years in ~110 centers
- >17,000 patients on LT waiting list
- ~1,800 deaths/year on waiting list last 3 years
- Mismatch between qualified candidates and available organs limits application of LT

# Reasons for Early Referral to Transplant Center

- Timely, stepwise evaluation of candidate
- Patient and family education about LT
- Intervention for confounding issues
  - Chemical dependence
  - Obesity and other medical issues
- Financial counseling
- Program selection by patient
  - Center-specific results, facilities, relationships with staff, etc.



Presentation of a variety of diseases

Initial workup includes paracentesis

 In cirrhosis onset of ascites predicts poor longterm prognosis

## **Cirrhosis**

- Anticipate complications
- Screen for varices, HCC
- Refer for liver transplant once index complication occurs

### **Key Issues in Liver Transplant**

- Indications
- Organ Allocation
- Care of the Cirrhotic Patient
- Recurrent Disease

Selection for Liver Transplantation

# **Contraindications to LT: Absolute**

- Active alcohol or substance abuse
- Advanced cardiopulmonary disease
- Systemic sepsis, unresponsive to Rx
- Multiorgan failure; multiple pressors
- Extrahepatic malignancy
- Severe pulmonary hypertension
- Severe psychiatric disease likely to affect compliance

# **Contraindications to LT: Relative**

- General debility
- Advanced age
- Extensive portal/mesenteric thrombosis
- Social isolation and limited support
- HIV seropositivity
- Cholangiocarcinoma